0001769759 false 0001769759 2023-10-20 2023-10-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 20, 2023

Monogram Orthopaedics Inc.

(Exact name of registrant as specified in its charter)

Delaware |  | 001-41707 |  | 81-3777260
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification Number)

3919 Todd Lane, Austin, TX 78744

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (512) 399-2656

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.001 per share |  | MGRM |  | The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure

On October 20, 2023, Monogram Orthopaedics Inc. (the “Company”) prepared a presentation regarding the business of the Company. This presentation is being made available publicly on the Company’s website located at ir.monogramorthopedics.com. A copy of that presentation is being furnished herewith as Exhibit 99.1.

Additionally, on October 20, 2023, the Company sent an email to its existing stockholders notifying them of the presentation regarding the business of the Company and providing certain other general updates on the Company. A copy of this email is being furnished herewith as Exhibit 99.2.

The Company also issued a press release on October 20, 2023 announcing the presentation, a copy of which is being furnished herewith as Exhibit 99.3.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. |  | Description
99.1 |  | Company presentation dated October 19, 2023
99.2 |  | Company letter to stockholders dated October 19, 2023
99.3 |  | Press release dated October 20, 2023
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| MONOGRAM ORTHOPAEDICS INC.
| By: | /s/Benjamin Sexson
| Name: Benjamin Sexson
| Title: Chief Executive Officer

Dated: October 20, 2023